-
21.发明授权Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof 失效吡喃葡萄糖氧基苄基苯衍生物，含有它们的药物组合物及其制备中间体公开(公告)号：US07129381B2
公开(公告)日：2006-10-31
申请号：US10978413
申请日：2004-11-02
申请人： Hideki Fujikura , Toshihiro Nishimura , Nobuhiko Fushimi , Kazuya Tatani , Norihiko Kikuchi , Kenji Katsuno , Masayuki Isaji
发明人： Hideki Fujikura , Toshihiro Nishimura , Nobuhiko Fushimi , Kazuya Tatani , Norihiko Kikuchi , Kenji Katsuno , Masayuki Isaji
CPC分类号： C07H15/203
摘要： The present invention relates to glucopyranosyl-oxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted(lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.
摘要翻译： 本发明涉及由以下通式表示的吡喃葡萄糖基 - 氧苄基苯衍生物：其中R 1表示氢原子，羟基，取代或未取代的氨基，氨基甲酰基，取代或未取代的（ 低级烷基）基团，取代或未取代的（低级烷氧基）基团等; R 2表示氢原子或低级烷基; 和R 3表示取代或未取代的（低级烷基）基团，取代或未取代的（低级烷氧基）基团，取代或未取代的（低级烷硫基）等，或其药学上可接受的盐，其中 在人SGLT2中具有抑制活性，并且可用作预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药剂，包含其的药物组合物及其中间体。
-
22.发明申请Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat 审中-公开引起肝脏异常积累的疾病进展抑制剂公开(公告)号：US20080045466A1
公开(公告)日：2008-02-21
申请号：US11572251
申请日：2005-07-19
IPC分类号： A61K31/7004 , A61P1/16
CPC分类号： A61K31/7028 , A61K31/155 , A61K31/4427 , A61K31/57 , A61K31/7036
摘要： The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.
摘要翻译： 本发明提供了可用作抑制与肝脂异常积累相关的疾病进展的药物的药物组合物。 特别地，作为活性成分含有钠/葡萄糖共转运体2抑制剂的本发明的药物组合物，作为抑制不仅普通脂肪肝而且还可以是非脂肪性脂肪性肝病 （NAFL），非脂肪性脂肪性肝炎（NASH），高营养性脂肪肝，糖尿病性脂肪肝，胆汁脂肪肝病毒性脂肪肝等。
-
23.发明授权Progression inhibitor for disease attributed to abnormal accumulation of liver fat 有权引起肝脏脂肪异常积累的疾病进展抑制剂公开(公告)号：US08951976B2
公开(公告)日：2015-02-10
申请号：US12511654
申请日：2009-07-29
IPC分类号： A61K31/70 , A61K31/7028 , A61K31/155 , A61K31/4427 , A61K31/57 , A61K31/7036
CPC分类号： A61K31/7028 , A61K31/155 , A61K31/4427 , A61K31/57 , A61K31/7036
摘要： The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcoholic fatty liver disease (NAFL), non-alcoholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcoholic fatty liver disease toxic fatty liver or the like.
摘要翻译： 本发明提供了可用作抑制与肝脂异常积累相关的疾病进展的药物的药物组合物。 特别地，作为活性成分含有钠/葡萄糖共转运体2抑制剂的本发明的药物组合物，作为抑制不仅普通脂肪肝而且还含有非酒精性脂肪性肝病 （NAFL），非酒精性脂肪性肝炎（NASH），营养性脂肪肝，糖尿病性脂肪肝，酒精性脂肪肝病毒性脂肪肝等。
-
-
搜索结果
23 条记录 (耗时 0.025 秒)
